Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors
Sharadha Subramanian(Novartis (Switzerland)), Savithri Ramurthy(FuelCell Energy (United States)), Daniel Poon(Rapt Therapeutics (United States)), Christopher M. McBride(Novartis (Switzerland)), Darrin D. Stuart(Scorpion Therapeutics (United States)), Barry H. Levine(Novartis (Switzerland)), Joelle Verhagen(Novartis (Switzerland)), Cynthia M. Shafer(Novartis (Switzerland)), Teresa E. Williams(Novartis (Switzerland)), Payman Amiri(Novartis (Switzerland)), Abran Costales(Novartis (Switzerland)), Paul A. Renhowe(Novartis (Switzerland))
Cited by 13
Related Papers
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492
Food, Shelter and Safety Needs Motivating Homeless Persons' Visits to an Urban Emergency Department
|Annals of Emergency Medicine|2008|100
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
|Cancer Discovery|2023|67
A Missense Mutation in the MBTPS2 Gene Underlies the X-Linked Form of Olmsted Syndrome
|Journal of Investigative Dermatology|2012|57